<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928329</url>
  </required_header>
  <id_info>
    <org_study_id>1307012371</org_study_id>
    <nct_id>NCT01928329</nct_id>
  </id_info>
  <brief_title>A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes</brief_title>
  <official_title>A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed pilot study is to determine whether glucose control can be improved
      with Bydureon treatment in patients with type I diabetes (T1D)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-site randomized placebo controlled trial of Bydureon in patients with type I
      diabetes (T1D) of at least 2 years duration who may or may not still have detectable levels
      of C-peptide during a mixed meal tolerance test (MMTT). Bydureon is a recently approved long
      acting form of Exenatide. Because of the lack of safety data for Bydureon in children, we
      propose to conduct the trial in adults (&gt;18 yrs.).

      Both the subject and the study personnel will be blinded to treatment assignment. The
      randomization will be done, 1;1, by the coordinating site (at Yale). As a secondary analysis,
      we propose to determine whether the presence of residual insulin production modifies the drug
      effect. To do this, we plan to stratify patients for randomization on the basis of detectable
      C-peptide levels. We will therefore wait for the results of the C-peptide levels from the
      enrollment MMTT prior to randomization. The study investigators will not be told in which
      stratum the patient is being randomized and will be blinded to the C-peptide results of the
      MMTT until the conclusion of the study.

      Note: The primary and study completion dates were changed 4/2016 to reflect an extension of
      the recruitment and accrual periods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in HbA1c Levels</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c Levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 mg, 1 per week via subcutaneous placebo self injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide (Bydureon)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg, of drug administration 1 per week via subcutaneous self injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide (Bydureon®)</intervention_name>
    <arm_group_label>Exenatide (Bydureon)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female aged 18-65 years who meets the American Diabetes Association standard
             T1DM criteria.

          -  Diagnosis of T1DM at least 2 years from Visit 0

          -  Insulin Requirement of ≤ 0.90 units/kg

          -  Absence of ketoacidosis in the past 6 months

          -  HbA1c of ≥ 6.5% and ≤ 9.5%

          -  Menstruating women must have a negative pregnancy test and be willing to avoid
             pregnancy during the study period

          -  Signed informed consent

        Exclusion Criteria:

          -  Inability or unwillingness to give informed consent

          -  Current or prior use of immunomodulators or systemic steroids in the last 6 months
             that could potentially affect diabetes or immunologic status.

          -  Known hypersensitivity to Exenatide, Liraglutide or any product component.

          -  Participation in an investigational treatment trial within the last 6 weeks before
             enrollment.

          -  1 or more episodes of hypoglycemia (loss of consciousness or requiring the help of
             others) within the last 6 months.

          -  Another condition that would, in the view of the investigator, affect the safety of
             using Bydureon. This might include, among others a history of MEN 2, a history of
             medullary carcinoma of the thyroid or pancreatitis.

          -  Known severe renal impairment, end-stage renal disease or renal transplantation.

          -  Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis,
             thyroid nodules or malignancy with the exclusion of a history of localized basal cell
             carcinoma.

          -  Uncompensated heart failure, fluid overload, myocardial infarction or liver disease
             within the last 6 weeks before enrollment.

          -  Clinically active serious infection.

          -  Positive pregnancy test in menstruating women or lactating females.

          -  Concurrent use of Pramlinitide, other Incretin medications, or other anti-diabetes
             medications other than insulin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Naomi S Yama, RN, BSN</last_name>
    <phone>203-737-2737</phone>
    <email>naomi.yama@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenna Auerback</last_name>
      <phone>844-813-8273</phone>
      <email>clinicalresearch@diabetes.ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Schauwecker</last_name>
      <email>Allison.schauwecker@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevan Herold, MD</last_name>
      <phone>203-785-6507</phone>
      <email>kevan.herold@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Matheson, RN, CDE</last_name>
      <phone>305-243-3781</phone>
      <email>dmatheso@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carlos Blaschke</last_name>
      <phone>305-243-4485</phone>
      <email>cblaschke@med.miami.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Grant</last_name>
      <email>tgrant@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Bryant</last_name>
      <phone>671-309-4141</phone>
      <email>Nora.Bryant@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <phone>(888)-813-8669</phone>
      <email>TrialNet@joslin.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Plunkett, RNC CCRC</last_name>
      <phone>734-936-8065</phone>
      <email>cplunket@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Pietropaolo</last_name>
      <phone>734-615-2528</phone>
      <email>supiet@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Massimo Pietropaolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzan Bzdick, RN, CCRC</last_name>
      <phone>315-464-9006</phone>
      <email>bzdicks@upstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Conboy, CCRC</last_name>
      <phone>315-464-9007</phone>
      <email>conboyp@upstate.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

